Anfield Capital Management, LLC Incyte Corp Transaction History

Anfield Capital Management, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 01, 2023	SELL	$67.18 - $84.11 $83,437 - $104,464	-1,242 Reduced 62.85%	734 $58,000
Q3 2022 Nov 09, 2022	BUY	$66.18 - $82.86 $3,970 - $4,971	60 Added 3.13%	1,976 $132,000
Q2 2022 Aug 09, 2022	BUY	$66.18 - $83.18 $31,634 - $39,760	478 Added 33.24%	1,916 $146,000
Q1 2022 May 13, 2022	BUY	$66.02 - $79.71 $94,936 - $114,622	1,438 New	1,438 $114,000

642

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.8B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Anfield Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Anfield Capital Management, LLC with notifications on news.